Study: Cancer Jab Eliminates Tumors in Patients
The Spin
Narrative A
Amivantamab is a genuine breakthrough for head and neck cancer patients who've exhausted every other option — tumors shrank in more than a third of patients, and survival stretched to a median of 12.5 months versus the typical three to six. A quick five-minute injection every three weeks with minimal side effects makes this treatment far more livable than chemotherapy, and it has the potential to help thousands of patients annually.
Narrative B
Amivantamab's trial results deserve cautious optimism, not celebration — only 15 of 102 patients saw tumors fully disappear, and the real test comes when this drug moves beyond tightly controlled trial conditions. The subcutaneous delivery and mild side-effect profile are genuinely promising practical advantages, but headline numbers like "tumors eliminated" create pressure to expand use beyond patients most likely to benefit.